CAR-T cell therapy for advanced gynecologic cancer with CD70 protein
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic gynecologic cancer that tested positive for a protein called CD70.
- Your cancer has progressed or you cannot tolerate standard treatments like surgery, chemotherapy, or radiation.
- You have at least one tumor that can be measured on a CT scan.
- You are generally well enough to be up and about for at least half the day (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This study tests an experimental therapy called SCT-001 CAR T cells, made from your own immune cells, for ovarian cancer that has not responded to standard treatments. The goal is to see if these engineered cells can find and attack your cancer cells, which could help shrink or control the disease.
This trial tests a new type of cell therapy called UCAR-T that targets a protein (CD70) found on many solid tumors. If you have advanced cancer that has not responded to standard treatments tricks and your tumor makes CD70, this experimental treatment may be an option.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.